This test is most useful if any of these apply to you.
If you have ever wondered whether the water you drink or the food you eat has left a chemical fingerprint inside your body, this is one of the markers that begins to answer that. It tracks one of the man-made 'forever chemicals' that accumulate in people over years and have been linked to higher cholesterol and changes in kidney and liver function.
This test measures how much PFNA (perfluorononanoic acid) is passing into your urine. That makes it a window into your exposure, but an imperfect one. PFNA clears from the body very slowly and often shows up in urine at extremely low levels or not at all, so a single number deserves cautious reading.
PFNA is a synthetic chemical, not something your body makes. It belongs to a large group of industrial compounds used since the mid-20th century in water-resistant fabrics, non-stick coatings, firefighting foams, and many other products. People take it in mainly through contaminated drinking water and food.
It earns the 'forever chemical' label because its carbon-to-fluorine bonds are unusually stable, so it resists breakdown and stays in the body and environment for a long time. European food-safety regulators consider it important enough to set a combined intake limit covering it and three related PFAS. A result here reflects your exposure and body burden.
PFNA is a long-chain PFAS, and these are notoriously hard to detect in urine because the amounts excreted there are so small. In one contaminated US community, PFNA was found in the blood of every participant but in only about 30 out of 100 urine samples. A national US study that paired blood and urine samples went further, finding long-chain PFAS like PFNA essentially undetectable in urine even in the general population. In a study of Austrian schoolchildren, the typical detectable level was below 0.0005 micrograms per liter, an extremely faint trace.
For this reason, blood is the matrix researchers rely on for PFNA, and a urine test is best treated as an exploratory exposure screen rather than a precise measure of how much you carry. There are no agreed clinical cutoffs for urinary PFNA, so a single reading should never drive a medical decision on its own. That is exactly why a baseline now, tracked over time, is more useful than any one value.
The most repeated human signal for PFNA is a link to worse cholesterol. In Norwegian adolescents, those in the highest exposure quarter had more than twice the odds of abnormal cholesterol as those in the lowest (odds ratio 2.30, 95% CI 1.16 to 4.57). In a contaminated US community, higher PFNA was tied to about 15% higher odds of self-reported high cholesterol.
In prediabetic adults, each doubling of PFNA in blood was associated with roughly 2.9 mg/dL higher total cholesterol. These findings all come from studies that measured PFNA in blood, not urine, so they describe the exposure your urine result is trying to reflect rather than the urine value itself. Laboratory cell experiments suggest PFNA can push liver cells to store more fat, which offers a plausible reason for the lipid link but is not human proof.
PFNA and the kidneys have a complicated relationship. In a large US survey, higher PFNA was tied to lower filtering capacity, measured as a lower estimated glomerular filtration rate (eGFR), a standard gauge of how well the kidneys clear waste. In people with chronic kidney disease, higher PFNA was linked to faster loss of kidney function.
Yet other studies point the opposite way: in young adults and in older adults, higher PFNA sometimes tracked with higher eGFR over time. This is not a simple good-number-bad-number marker. Because the kidneys are what clear PFNA, weaker kidneys can let it build up, which can make it look like the chemical caused the change when the direction may run backward. Researchers read the higher-filtration pattern as early kidney stress, not a benefit, and agree the picture is nonlinear.
A pooled analysis of human studies found that higher PFNA exposure was associated with higher ALT, a liver enzyme that rises when liver cells are under stress (this association was statistically significant, p=0.023). The effect was smaller than for two other PFAS studied alongside it. As with the lipid findings, this evidence comes from blood-based measurements, so it speaks to PFNA exposure broadly rather than to the urine value specifically.
PFNA is one of the most commonly detected PFAS in pregnancy. Higher blood PFNA has been linked to about 32% higher odds of a baby being born smaller than expected for its gestational age per doubling of exposure (odds ratio 1.32, 95% CI 1.07 to 1.63). In one birth cohort, higher PFNA was tied to a specific type of preterm birth (odds ratio 1.67, 95% CI 1.06 to 2.61) and stood out as the most influential PFAS in the mixture.
Studies of placental tissue also link PFNA to markers of placental stress. These are observational findings measured in blood, and some meta-analyses find the pregnancy associations inconsistent, so they signal concern rather than certainty.
In one prospective multiethnic study, people with the highest PFNA levels had a higher risk of kidney cancer (odds ratio 1.84 comparing highest to lowest quarter), with the strongest link among African American participants. A separate large cancer cohort found no clear overall PFNA-cancer association; in that study the kidney cancer link was with a different PFAS, not PFNA. The evidence is real but unsettled, and again rests on blood measurements.
A single urine PFNA value is easy to misread. The chemical is often near or below the detection limit, and the concentration in a spot sample rises or falls with how much you have had to drink. Because PFNA leaves the body over years, meaningful change shows up as a trajectory, not a one-time snapshot.
Get a baseline, then retest in 6 to 12 months if you change your water source or other exposures, and periodically after that to confirm the trend is heading down. One caveat matters: the direct evidence that PFNA levels fall after you cut off an exposure comes from blood testing. If your goal is to prove an intervention is working, a blood PFAS test is the more dependable way to watch that decline.
A detectable or elevated urinary PFNA is a cue to look for the source, not a diagnosis. Start with your water: private wells and locally contaminated supplies are the clearest drivers, and testing your water or adding certified filtration addresses the input directly. Consider a blood PFAS panel to confirm your true body burden, since urine can miss it.
Pair the result with companion labs to see whether any downstream effects are showing up: a lipid panel, kidney testing that includes eGFR and cystatin C, and liver enzymes. If several of these drift together, that combination is more actionable than any single number, and it is worth involving an environmental-health or toxicology specialist, and a kidney specialist if your filtering markers are off.
Evidence-backed interventions that affect your Perfluorononanoic acid (PFNA) level
Perfluorononanoic acid (PFNA) is best interpreted alongside these tests.
Perfluorononanoic acid (PFNA) is included in these pre-built panels.